Scalper1 News
Regeneron Pharmaceuticals (REGN) popped in the stock market today, but shares are hitting resistance at a key level. The biotech now faces less competition for its cholesterol drug, as Eli Lilly (LLY) is discontinuing development of its heart-disease treatment, which RBC Capital Markets notes is a big benefit for Regeneron and its larger peer Amgen (AMGN). Regeneron gapped up 5.2% in heavy volume on Monday. But the stock looks to be finding Scalper1 News
Scalper1 News